In Mixed Ruling for
In Mixed Ruling for NCLA Clients, District Judge Says CFPB Rule Does Not Apply in Sixth Circuit
May 17, 2021 17:36 ET | New Civil Liberties Alliance
Washington, D.C., May 17, 2021 (GLOBE NEWSWIRE) -- The New Civil Liberties Alliance is celebrating a partial win for housing providers in Kentucky, Michigan, Ohio, and Tennessee. The U.S. District...
logo.jpg
ImCheck Announces Initiation of U.S. Enrollment in Phase I/IIa EVICTION Trial for ICT01
April 26, 2021 05:00 ET | ImCheck Therapeutics SAS
ImCheck Announces Initiation of U.S. Enrollment in Phase I/IIa EVICTION Trial for ICT01 -- EVICTION is a multi-center trial evaluating Butyrophilin 3A-targeted activation of the anti-tumor immune...
logo.jpg
ImCheck to Present Data Demonstrating Activation of the Anti-Tumor Immune Response of Gamma9 Delta2 T Cells in Cancer Patients from the Ongoing Phase I/IIa EVICTION Trial at the AACR Annual Meeting 2021
March 11, 2021 05:00 ET | ImCheck Therapeutics SAS
ImCheck to Present Data Demonstrating Activation of the Anti-Tumor Immune Response of Gamma9 Delta2 T Cells in Cancer Patients from the Ongoing Phase I/IIa EVICTION Trial at the AACR Annual Meeting...
NCLA Appeals to Stop
NCLA Appeals to Stop the Radical Intrusion on State Courts Caused by CDC’s Eviction Moratorium
December 21, 2020 20:54 ET | New Civil Liberties Alliance
Washington, D.C., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Using the pandemic emergency as an excuse, the Centers for Disease Control and Prevention (CDC), a part of the U.S. Department of Health and Human...
logo.jpg
ImCheck Announces Four ICT01 Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting
October 14, 2020 17:00 ET | ImCheck Therapeutics SAS
Marseille, France, October 14, 2020 – ImCheck Therapeutics today announced the acceptance of four clinical and preclinical data abstracts on its proprietary drug candidate ICT01 at the Society for...
logo.jpg
ImCheck Announces Investment by BB Pureos Bioventures to Close Series B Fundraising with Total of €54 million ($64 million)
September 15, 2020 05:00 ET | ImCheck Therapeutics SAS
ImCheck Announces Investment by BB Pureos Bioventuresto Close Series B Fundraising with Total of €54 million ($64 million) Marseille, France, September 15, 2020 – ImCheck Therapeutics today announced...
logo.jpg
ImCheck Achieves Initial Positive Independent Safety Review and Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01
September 10, 2020 05:46 ET | ImCheck Therapeutics SAS
ImCheck Achieves Initial Positive Independent Safety Reviewand Initiates Next Stage of Phase I/IIa EVICTION Trial for ICT01                        Company Receives FDA Approval for US IND ...
NCLA Challenges Unla
NCLA Challenges Unlawful CDC Order that Leaves Landlords Powerless to Evict Delinquent Tenants
September 08, 2020 15:17 ET | New Civil Liberties Alliance
Washington, D.C., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Today the New Civil Liberties Alliance, a nonpartisan, nonprofit civil rights group, filed a complaint and request for a temporary restraining...
Color_highres_horizontal.png
The Only Tenant Protection in Ontario’s Bill 184 is in the Title
May 28, 2020 11:00 ET | Advocacy Centre for Tenants Ontario
TORONTO, May 28, 2020 (GLOBE NEWSWIRE) -- In the middle of a pandemic crisis, the Ontario government made a sudden decision to revive their makeover of landlord-tenant law, Bill 184 “Protecting...
logo.jpg
HalioDx's expertise applied to ImCheck’s EVICTION Trial
May 19, 2020 07:50 ET | HalioDx
HalioDx to Characterize the Immune Contexture ofPatients Enrolled in ImCheck’s EVICTION Phase 1/2 Clinical Trial HalioDx’s immunoscoring technologies  to characterize patients treated with ImCheck’s...